Publications by authors named "A L Michan"
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study.
Lancet Diabetes Endocrinol
September 2024
Article Synopsis
- * Analysis showed that while LDL-cholesterol reductions over time were similar for both sexes, a higher percentage of males had existing cardiovascular disease both at enrollment and during follow-up compared to females.
- * Notably, males experienced their first ASCVD event at a median age of 50.6 years, significantly earlier than females, who had their first event at a median age of 61.6 years, highlighting important sex-related differences in
Article Synopsis
- * Out of 696 patients studied, a high persistence rate of 96.1% with PCSK9i treatment was observed over a median follow-up of 3.7 years, leading to significant reductions in LDL-C levels.
- * The treatment not only improved cholesterol management, with 77% reaching 2016 LDL-C goals, but also maintained a good quality of life for the patients throughout the study period.
Aims: Knowledge of the features of patients with familial hypercholesterolaemia (FH) who are protected from atherosclerotic cardiovascular disease (ASCVD) is important for the clinical and prognostic care of this apparently high-risk condition. Our aim was to investigate the determinant and characteristics of patients with FH who are protected from ASCVD and have normal life expectancy, so-called 'resilient' FH (R-FH).
Methods And Results: Spanish Familial Hypercholesterolaemia cohort study (SAFEHEART) is an open, multicentre, nation-wide, long-term prospective cohort study in genetically defined patients with heterozygous FH in Spain.
Introduction And Objectives: The SAFEHEART study was designed to analyze the situation of familial heterozygous hypercholesterolemia (FHH) and improve knowledge of this disease in Spain. Our objective was to determine the incidence rate of cardiovascular events, the estimated risk of developing an event and its modification, the use of lipid-lowering treatment, and the achievement of low-density lipoprotein cholesterol targets in patients with FHH.
Methods: SAFEHEART is a prospective, open, multicenter, nationwide cohort study, with long-term protocol-based follow-up in a population of individuals with molecularly-characterized FHH.